ANGLE partners with AstraZeneca in groundbreaking oncology contract
–News Direct–
ANGLE PLC chief executive Andrew Newland joins Proactive's Stephen Gunnion with news the company has entered a significant contract with AstraZeneca, marking its second major collaboration with a large pharmaceutical company.
Newland, expressed enthusiasm about this development, noting the contract's potential to expand ANGLE's services in oncology trials. The initial phase of the contract is valued at 150,000, but it holds substantial potential due to the possibility of implementing a new assay in numerous cancer trials involving AstraZeneca. The scope of the collaboration includes the development of assays for examining proteins on cancer cells across multiple trials, with potential earnings of 2,000 per time point in over 460 trials.
The contract...